Abstract #4721
Verification of impaired vasoreactivity in subjects with Cerebral Amyloid Angiopathy: A post-hoc analysis of visual-stimulus fMRI
James A Goodman 1 , Mark R Austin 2 , Andrea S Les 2 , Zhiyong Xie 1 , Yao Zhang 3 , and Claire Leurent 4
1
Precision Medicine - Clinical and
Translational Imaging, Pfizer Inc, Groton, CT, United
States,
2
IXICO
plc, London, United Kingdom,
3
PharmaTherapeutic
Statistics, Pfizer Inc, Cambridge, MA, United States,
4
Neuroscience
Research Unit, Pfizer Inc, Cambridge, MA, United States
Cerebral amyloid angiopathy (CAA) is characterized by
cerebrovascular amyloid deposition and has been shown to
be associated with reduced cerbrovascular reactivity in
transgenic animal models and in a cohort of human
subjects. In this work we attempt to replicate
previously-published findings in an independent cohort
of CAA subjects and age-matched controls by performing a
retrospective analysis of the ascending slope of the
hemodynamic response to visual stimulus fMRI. Despite
differing field strengths, acquisition protocols and
analysis pipelines, a similar observation of
significantly reduced cerebrovascular reactivity was
observed, demonstrating the robust nature of this
characteristic of CAA.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
